Skip to content Skip to footer

Archer Materials Ltd

Share Price and News

ASX BIG FOUR - LIVE SNAPSHOT

SELL

Whitehaven Coal

(ASX:WHC)

Paul Flynn
01/03/2026
$8.7m
BUY

Elixir Energy

(ASX:EXR)

Featured
SELL

Aspen Group

(ASX:APZ)

David Dixon
03/03/2026
$11.4m
BUY

Lovisa

(ASX:LOV)

Brett Blundy
04/03/2026
$6.8m
Copmany Overview

About Archer Materials

Archer Materials (ASX: AXE) is a company commercialising two devices. The first is 12CQ, a carbon-based semiconductor technology which could enable mobile quantum devices. It resolves the impediments that have prevented quantum devices, from reaching the mainstream – which currently include the practicalities of operation and scale. Second is Biochip, a Lab-on-a-Chip technology being developed to enable rapid, detection of diseases. It would allow droplets of biological specimens to be analysed and processed using graphene sensors, thus generating faster and more reliable results than competing technologies. Archer Materials is the only ASX-listed company, and one of only a few companies in the world attempting to develop such technologies. It has a well-rounded patent portfolio, a proven record of cost control and crucial partnerships with foundries and research partners. Most crucially, it has a very substantial revenue opportunity ahead of it.

Archer Materials Company History

Founded in 2007, Archer Materials initially began its journey focusing on material science and the development of advanced technologies for the electronics industry. Over the years, the company expanded its research to include the high-tech fields of quantum computing and energy storage solutions. By 2019, it had pivoted completely to its current product suite. Driving the company’s value has been technical achievements recorded with both products. With 12CQ, early milestones included demonstrating quantum information detection on-chip and advancing nanofabrication compatible with industry semiconductor processes. More recent progress has seen Archer achieve key technical steps such as single-electron isolation, enhanced spin control and extended coherence times at room temperature – all critical steps towards building a functional quantum device. With Biochip, Archer has already produced an alpha prototype capable of clinically accurate blood potassium sensing using very small sample volumes, meeting standards that could make it viable for point-of-care or home diagnostics. Next steps include completing a beta prototype in 2026, which will be key for pursuing commercial partnerships with MedTech firms. Archer’s technical milestones over the years include working with strategic fabrication partners and research institutes (including IMEC, CSIRO and Emergence Quantum), miniaturising its Biochip design for foundry manufacturing, and progressing both device architecture and CMOS integration for commercial scalability.

Get Our Full ASX Stock Analysis Report

Expert buy ranges, stop losses and detailed fundamentals for 200+ ASX stocks – free every week.

Forward View

Future Outlook of Archer Materials Ltd (ASX:AXE)

Archer’s outlook depends on the progress with 12CQ and Biochip. Management and industry watchers are treating 2026 as an inflection year where research activity transitions into more product-ready demonstrations and early commercial engagement – a watershed phase for any early-stage deep tech company. Specifically, 2026 is expected to see a beta prototype and progress towards clinical trials for Biochop. As for 12CQ, continued progress in 2026 toward a functional quantum bit demonstration and scalable device architecture. Archer’s prospects are tied to deep tech and quantum computing trends where global R&D spending is forecast to grow, and where breakthroughs that reduce complexity and cost (such as room-temperature qubit operation) are highly prized by industrial, defence and scientific users. Separately, the biosensor and diagnostics market is expanding rapidly due to aging populations and chronic disease prevalence, favouring point-of-care innovations like Archer’s Biochip.

Our Assessment

Is Archer Materials a Good Stock to Buy?

Archer Materials is fundamentally a speculative, deep-tech investment rather than a traditional commercial company. It does not yet generate meaningful product revenue from its core technologies – the 12CQ quantum technology and the Biochip medical diagnostics platform – and continues to operate at a loss with ongoing R&D expenditure typical of pre-commercial technology developers. Its upside lies in successful execution of all that it has promised and eventual commercialisation. But the company is highly speculative and its earnings are only on its potential. Archer Materials may be suitable for investors with a high risk tolerance and a long investment horizon who are comfortable with binary outcomes. It is not a conventional income or value stock, and it is not currently positioned as a stable, profit-generating business.

Our Stock Analysis

Nanoveu (ASX:NVU) 16nm chip enters TSMC fabrication, A$7.5m raise funds the validation push

Design completion is not the milestone that moves a semiconductor company from interesting to credible.…

DorsaVi (ASX:DVL) Ultra Edge AI Could Unlock a Re-Rate Toward Our Base Valuation

DorsaVi (ASX:DVL) holds two IP acquisitions in ReRAM and neuromorphic AI. We value the stock…

Celestica (NYSE:CLS) The AI Infrastructure Winner No One Wanted This Quarter

Celestica (NYSE:CLS) posted 53% revenue growth and a record 8% margin in Q1 2026, but…

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors…

Apple’s New Era: What the Tim Cook to John Ternus Transition Means for the World’s Most...

Apple (NASDAQ: AAPL) has confirmed that Tim Cook will step down as chief executive officer…
Faq

Frequently Asked Questions

What makes Archer Materials a unique company?
Archer Materials stands out for its focus on developing advanced semiconductor materials, particularly those for quantum computing and energy storage. Its innovations have the potential to revolutionise multiple high-tech industries.
Archer is one of the few companies developing materials for quantum computing, specifically semiconductors capable of creating qubits. This positions the company as a leader in the growing quantum tech field.
Archer Materials presents a promising opportunity for investors, particularly those seeking exposure to emerging technologies like quantum computing and advanced semiconductors. However, like any tech company, there are risks, and investors should carefully consider these before making an investment.
Archer Materials’ growth strategy involves continuing to innovate in the semiconductor and quantum computing sectors while expanding into energy storage. The company also seeks to build strategic partnerships to accelerate the commercialisation of its technologies.
Archer Materials is fundamentally a speculative deep-tech investment. Key risks include the long commercialisation timelines typical of semiconductor and biosensor technology, the capital-intensive nature of bringing quantum and chip-based devices to market, competition from much larger global players with greater R&D resources, and the possibility that technical milestones slip or fail to translate into scalable products.

Stay Sharp on the ASX

Weekly research. Independent analysis. No noise.

Free forever · Unsubscribe anytime

© 2026 Kicker. All Rights Reserved.

Add Your Heading Text Here